15 April 2021, 22:30 CEST, Adelaide, Australia and Liege, Belgium: Mayne Pharma Group Limited (ASX: MYX) and Mithra Pharmaceuticals, SA (Euronext Brussels: MITRA) are very pleased to announce that the US Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for the novel combined oral contraceptive Estelle® under the trademark Nextstellis® (15 mg Estetrol (E4) / 3 mg drospirenone (DRSP)). Mayne Pharma anticipates the commercial launch of Estelle® by the end of June 2021.
https://www.mithra.com/wp-content/uploads/2019/09/USA-flag.jpg 1282 1920 Mithra Pharmaceuticals https://www.mithra.com/wp-content/uploads/2017/05/logo-mithra-women-s-health.png Mithra Pharmaceuticals2021-04-15 22:30:092021-04-15 22:32:08Mayne Pharma and Mithra Announce FDA Approval of New Oral Contraceptive Estelle®
Rue Saint-Georges 5
Tel. : +32 (0)4 349 28 22
Fax : +32 (0)4 349 28 21
Email : email@example.com